{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T20:43:22Z","timestamp":1760647402181,"version":"3.41.2"},"reference-count":34,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T00:00:00Z","timestamp":1613001600000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Res &amp; Perspec"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>The ORBITA trial of percutaneous coronary intervention (PCI) versus a placebo procedure for patients with stable angina was conducted across six sites in the United Kingdom via home monitoring and telephone consultations. Patients underwent detailed assessment of medication adherence which allowed us to measure the efficacy of the implementation of the optimization protocol and interpretation of the main trial endpoints.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Prescribing data were collected throughout the trial. Self\u2010reported adherence was assessed, and urine samples collected at pre\u2010randomization and at follow\u2010up for direct assessment of adherence using high\u2010performance liquid chromatography with tandem mass spectrometry (HPLC MS\/MS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Self\u2010reported adherence was &gt;96% for all drugs in both treatment groups at both stages. The percentage of samples in which drug was detected at pre\u2010randomization and at follow\u2010up in the PCI versus placebo groups respectively was: clopidogrel, 96% versus 90% and 98% versus 94%; atorvastatin, 95% versus 92% and 92% versus 91%; perindopril, 95% versus 97% and 85% versus 100%; bisoprolol, 98% versus 99% and 96% versus 97%; amlodipine, 99% versus 99% and 94% versus 96%; nicorandil, 98% versus 96% and 94% versus 92%; ivabradine, 100% versus 100% and 100% versus 100%; and ranolazine, 100% versus 100% and 100% versus 100%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Adherence levels were high throughout the study when quantified by self\u2010reporting methods and similarly high proportions of drug were detected by urinary assay. The results indicate successful implementation of the optimization protocol delivered by telephone, an approach that could serve as a model for treatment of chronic conditions, particularly as consultations are increasingly conducted online.<\/jats:p><\/jats:sec>","DOI":"10.1002\/prp2.710","type":"journal-article","created":{"date-parts":[[2021,2,14]],"date-time":"2021-02-14T02:53:38Z","timestamp":1613271218000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Achieving optimal adherence to medical therapy by telehealth: Findings from the ORBITA medication adherence sub\u2010study"],"prefix":"10.1002","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0850-7784","authenticated-orcid":false,"given":"David","family":"Thompson","sequence":"first","affiliation":[{"name":"National Heart and Lung Institute Imperial College London London UK"},{"name":"Institute of Cardiovascular Science University College London London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rasha","family":"Al\u2010Lamee","sequence":"additional","affiliation":[{"name":"National Heart and Lung Institute Imperial College London London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Foley","sequence":"additional","affiliation":[{"name":"National Heart and Lung Institute Imperial College London London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hakim M.","family":"Dehbi","sequence":"additional","affiliation":[{"name":"Comprehensive Clinical Trials Unit at UCL University College London London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Thom","sequence":"additional","affiliation":[{"name":"National Heart and Lung Institute Imperial College London London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin E.","family":"Davies","sequence":"additional","affiliation":[{"name":"National Heart and Lung Institute Imperial College London London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darrel P.","family":"Francis","sequence":"additional","affiliation":[{"name":"National Heart and Lung Institute Imperial College London London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prashanth","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Chemical Pathology and Metabolic Diseases University Hospitals of Leicester Leicester UK"},{"name":"Department of Cardiovascular Sciences University of Leicester Leicester UK"},{"name":"NIHR Leicester Biomedical Research Unit in Cardiovascular Disease Leicester UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pankaj","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Chemical Pathology and Metabolic Diseases University Hospitals of Leicester Leicester UK"},{"name":"Department of Cardiovascular Sciences University of Leicester Leicester UK"},{"name":"NIHR Leicester Biomedical Research Unit in Cardiovascular Disease Leicester UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"ORBITA Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,2,11]]},"reference":[{"volume-title":"Adherence to long\u2010term therapies: evidence for action","year":"2003","author":"Yach D","key":"e_1_2_11_2_1"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.06.005"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.05.030"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/pubmed\/fdy088"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000232"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2011.09.051"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1999.tb01558.x"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32714-9"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.4244\/EIJV13I11A195"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.601"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.114.000882"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcq011"},{"key":"e_1_2_11_14_1","first-page":"346","article-title":"SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials","volume":"2013","author":"Chan A\u2010W","year":"2013","journal-title":"BMJ"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.104.521864"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-198601000-00007"},{"key":"e_1_2_11_17_1","article-title":"Protocol 15PRT\/06897: objective randomised blinded investigation with optimal medical therapy of angioplasty in stable angina (ORBITA trial) \u2010 NCT02062593 [Protocol]","author":"Francis DP","year":"2016","journal-title":"Lancet"},{"issue":"38","key":"e_1_2_11_18_1","first-page":"2975","article-title":"2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology","volume":"34","author":"Montalescot G","year":"2013","journal-title":"Eur Heart J"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.99.21.2829"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.277064"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2013-305063"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz748.0070"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.768986"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.113.000697"},{"key":"e_1_2_11_25_1","first-page":"19","article-title":"Interventions for enhancing medication adherence","volume":"11","author":"Nieuwlaat R","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_11_26_1","unstructured":"NIHR.HTA Funding Committee Public Minutes 19\u201320 May 2020.2020.https:\/\/www.NIHR.ac.uk\/documents\/hta\u2010funding\u2010committee\u2010public\u2010minutes\u201019\u201020\u2010may\u20102020\/25078?pr=. Accessed 14\/08\/2020."},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915922"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra050100"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy339"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2012.03.059"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-016-0697-7"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.048185"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30818-7"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2003539"},{"key":"e_1_2_11_35_1","unstructured":"Al\u2010lameeR.Summary and contact.2020.https:\/\/www.imperial.ac.uk\/people\/r.al\u2010lamee13."}],"container-title":["Pharmacology Research &amp; Perspectives"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.710","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/prp2.710","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.710","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T00:28:14Z","timestamp":1693700894000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/prp2.710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1002\/prp2.710"],"URL":"https:\/\/doi.org\/10.1002\/prp2.710","archive":["Portico"],"relation":{},"ISSN":["2052-1707","2052-1707"],"issn-type":[{"type":"print","value":"2052-1707"},{"type":"electronic","value":"2052-1707"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"2020-10-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00710"}}